Reshaping the HIV treatment and prevention landscape
RSV Older Adults: potential first- and best-in class £multi-billion opportunity
Leveraging our proven adjuvant technology
gsk
One of the highest value, unmet need
remaining in infectious diseases
Higher risk of severe outcomes than Influenza1
% of patients
hospitalised who
FLU
stay ≥7 days1
RSV
% of hospitalised
FLU
14%
patients admitted to
intensive care1
RSV
18%
RSV OA: £5bn market opportunity**
31%
43%
Most advanced RSV OA vaccine candidate
in Phase 3 with best-in class potential
—
Pre-fusion F antigen combined with proven
AS01 adjuvant in older adults
- Positive Phase 2 data:
-
- Adjuvanted approach boosts neutralising
antibodies ~10x with T-cell restoration
similar in range to young adults
- FDA fast-track designation; launch in 2024*
>1bn 60+ people globally exposed to RSV annually
-
Planning for expanded adult indications &
combinations with other adult vaccines
1. Higher risk of severe outcomes than influenza in hospitalised patients - Ackerson et al. Clin Infect Dis. 2019;69(2):197 2. United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019,
custom data acquired via website.
*subject to regulatory approval; **GSK estimate for total RSV OA market
66View entire presentation